173 related articles for article (PubMed ID: 26254108)
1. Direct effects of DPP-4 inhibition on the vasculature. Reconciling basic evidence with lack of clinical evidence.
Fadini GP; Albiero M; Avogaro A
Vascul Pharmacol; 2015 Oct; 73():1-3. PubMed ID: 26254108
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
Penno G; Garofolo M; Del Prato S
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Koska J; Sands M; Burciu C; Reaven P
Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133
[TBL] [Abstract][Full Text] [Related]
4. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
Bae EJ
Arch Pharm Res; 2016 Aug; 39(8):1114-28. PubMed ID: 27502601
[TBL] [Abstract][Full Text] [Related]
5. Blood pressure-lowering effects of incretin-based diabetes therapies.
Lovshin JA; Zinman B
Can J Diabetes; 2014 Oct; 38(5):364-71. PubMed ID: 25284699
[TBL] [Abstract][Full Text] [Related]
6. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases.
Xie W; Song X; Liu Z
Vascul Pharmacol; 2018 Oct; 109():17-26. PubMed ID: 29879463
[TBL] [Abstract][Full Text] [Related]
7. Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines.
Packer M
Cardiovasc Diabetol; 2018 Jan; 17(1):9. PubMed ID: 29310647
[TBL] [Abstract][Full Text] [Related]
8. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.
Omar B; Ahrén B
Diabetes; 2014 Jul; 63(7):2196-202. PubMed ID: 24962916
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase IV inhibitors and ischemic myocardial injury.
Yoon AH; Ye Y; Birnbaum Y
J Cardiovasc Pharmacol Ther; 2014 Sep; 19(5):417-25. PubMed ID: 24607763
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
Fadini GP; Avogaro A
Vascul Pharmacol; 2011; 55(1-3):10-6. PubMed ID: 21664294
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes.
Scheen AJ
Eur J Intern Med; 2012 Mar; 23(2):126-31. PubMed ID: 22284241
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects of the DPP-4 inhibitors.
Jose T; Inzucchi SE
Diab Vasc Dis Res; 2012 Apr; 9(2):109-16. PubMed ID: 22337893
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
15. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
Balakumar P; Dhanaraj SA
Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531
[TBL] [Abstract][Full Text] [Related]
17. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease.
Panchapakesan U; Mather A; Pollock C
Clin Sci (Lond); 2013 Jan; 124(1):17-26. PubMed ID: 22963445
[TBL] [Abstract][Full Text] [Related]
18. DPP-4 inhibitors in the treatment of type 2 diabetes.
Duez H; Cariou B; Staels B
Biochem Pharmacol; 2012 Apr; 83(7):823-32. PubMed ID: 22172989
[TBL] [Abstract][Full Text] [Related]
19. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
20. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S
Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
